

Diltiazem suspension 12 mg/mL (50 mL)

Patient's name		•	Storage condition		In a refrigerator			At room temperature	
NHI				Temperature		2-8°C		≤ 25°C	
Date compounded				Shelf life		30 days		30 days	
Batch number				Recommended storage		\checkmark		May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided	
Ingredients required	and formula	a:		r —		r	r		
Ingredient	Supplier	Batch number	Expiry date	Stan forn	ndard nula	Quantity dispensed	Dispe by	ensed	Checked by
Diltiazem 60 mg tablets				10	tablets				
Ora-Blend [®]	Perrigo			to	50 mL				
OR	- 1					I			
Ora-Plus [®]	Perrigo				25 mL				
Ora-Sweet [®]	Perrigo				25 mL				
Ora-Blend SF [®] or Or	a-Sweet SF®	(sugar free) can b	be substituted	?	Yes				
Calculations perform									
Calculations checked by (pharmacist)									
Area cleared for processing by									
 Crush tablet Add diluent Gradually ac Make up to 	I[®] unavailabl ts in mortar to (Ora-Blend [®] dd the diluen the final volu	nsion: e : Pre-mix the O o a fine powder. or prepared diluc t and transfer to ime and mix well ict appropriately.	ent) to form a the final meas	smoo	oth paste	2.		ell. Mi>	cwell.
Labels									
Attach product labe	y labels:						Label	checked by	



Diltiazem suspension 12 mg/mL (50 mL)

Final yield		mL		Checked by					
Final appearance of product		Pale white suspension (Dilzem [®]).							
Container		Amber plastic mission bottle / amber glass.							
Compounded by		Name:	Sigi	nature:	Date:				
Final check and product release		Name:	Sigi	nature:	Date:				
Special instructions:									
 Shake well before use. Store in a refrigerator. 									
 References: 1. Allen LV, Jr., Erickson MA, 3rd. Am J Health Syst Pharm, 1996; 53(18): 2179-84. 2. Allen LV, Jr., Erickson MA, 3rd. Secundum Artem; 6(1). 									
Prepared by	New Zealand Compounding Working Group								
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ								
Hosted by	Pharmaceutical Society of New Zealand <u>Standard Formulations in the Practice Support section of the PSNZ website</u>								
Version number	3.0		Version approval date 17/07/19		17/07/19				
Document review due	01/08/21								

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.